Pioneers in pulsed field ablation

Over 15 years of robust preclinical research in irreversible electroporation (IRE) and clinical application of pulsed field cardiac ablation has yielded PulseSelect™ pulsed field ablation system, the first and only PFA system approved in the U.S. for paroxysmal and persistent AF, and the approval of the Affera™ mapping and ablation system integrated with the only all-in-one dual-energy Sphere-9™ catheter. The Medtronic PFA suite launches a new era in safety and an exciting shift in precision and efficiency in AFib treatment.


0:00 / 0:00


Versatile PFA tools to tailor lesion sets

Wide area focal

Wide area focal catheters provide the ability to tailor lesions sets across the anatomy and provide consistent and reliable isolation. 

An all-in-one solution to map, ablate, and validate. Sphere-9™ catheter is the only wide area focal dual-energy PF/RF catheter and is integrated with the Affera™ mapping and ablation system. 

This is an image of the Affera™ mapping system demonstrating the wide area focal dual energy PF/RF catheter making tailored lesion sets.

SPHERE Per-AF — superior efficiency compared to traditional RF1

RCT IDE comparing Affera™ mapping and ablation system with Sphere-9™ to Carto®* with Thermocool STSF™*

420 patients | drug-refractory persistent AF | 23 centers | 40+ operators

  • 1.4% primary safety events vs 1% when using STSF
  • 74% primary effectiveness rate
  • 80% effectiveness in more than 10 cases2
  • 25+ minutes saved per procedure


Single shot

Single-shot PFA catheters allow you to achieve wide area circumferential lesions designed with PVI in mind. 

PulseSelect™ pulsed field ablation system is a single-shot over-the-wire PF catheter enabling mapping and precise lesion delivery with the freedom to adapt to your preferred workflow. 

This is an image of the PulseSelect™ pulsed field ablation (PFA) system being used in the body.

PULSED AF — the safest PFA IDE trial published to date.3

IDE evaluating the safety and effectiveness of the PulseSelect™ PFA system.

300 patients | drug-refractory PAF and PsAF patients | 41 centers | 67 operators


Primary safety events

0.7%


Efficacy

Freedom from AF/AT/AFL

This is a bar chart showing the efficacy data from the PULSED AF clinical trial.


Medtronic PFA history


Related products